课题基金 / 基金详情

以“多成分-多靶点”模式构建双向筛选评价体系解析莪术-三棱药对抗肺癌的药效物质

批准号:
82104544
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
林园园
依托单位:
学科分类:
中药学研究新技术与新方法
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
林园园

项目摘要

结项摘要

林园园的其他基金

相似基金

相关文献

中文摘要
中药药效物质不明是中药现代研究的关键科学问题。目前药效物质筛选多为单向筛选体系(靶点已知、药效物质未知),难以阐释中药多成分-多靶点特性。我们近期研究表明亲和反应靶点稳定技术(DARTS)在对小分子不做改造下可从肿瘤细胞总蛋白中筛选出目标蛋白。本项目拟将DARTS原理与中药药效物质筛选理念相结合,在靶点和药效物质均未知情况下,构建“多成分-多靶点”模式的双向筛选体系研究莪术-三棱药对抗肺癌的药效物质和作用靶点。将药对提取物与肺癌A549细胞总蛋白孵育,用特定蛋白水解酶酶解游离蛋白,有效成分-靶蛋白复合物因对酶稳定被保留,解离超滤获得的复合物,高分辨质谱分别鉴定解离后的有效成分群和靶蛋白群,活性实验验证有效成分群抗肺癌的活性及整合作用,表面等离子体共振及分子对接等技术验证有效成分与作用靶点的对应关系。本项目不仅有助于发现该药对抗肺癌的药效物质,也可弥补中药药效物质目前只能单向筛选的不足。
英文摘要
Discovery of active components was the key scientific problem in the modernization of traditional Chinese medicines. The methods for screening the active components in traditional Chinese medicines were mostly one-way screening system (targets are known, active components are unknown), and it is difficult to explain the characteristic of multiple components-multiple targets of traditional Chinese medicines. The targets were screened from the cancer cell lysates without any modification of small molecules via the affinity response target stabilization technology (DARTS) in our recent study. DARTS was combined with the concept of screening active components in traditional Chinese medicines in this project, a two-way screening system with a “multiple components-multiple targets” model would be established to screen the anti-lung cancer components in Curcumae rhizoma-Sparganii rhizome herbal pair and the targets. The extracts of the herbal pair were incubated with the total protein of A549 cells, pronase was used to digest the free protein, the active component-target complexes were survived due to the better stability. The complexes were dissociated and separated then, the active components and the targets were identified respectively by high resolution mass spectrometry. The anti-lung cancer activities of these components were verified by following pharmacology experiments, the relationship between the active component and the target was verified by surface plasmon resonance and molecular docking techniques. The anti-lung cancer active components and targets could be screened simultaneously in this project, and it also provided the solution for the shortage of the screen method of traditional Chinese medicines.
中药药效物质的发现及评价是中药现代化研究的重要内容之一,中药药效物质的筛选发现与中药的作用靶标挖掘是实现上述内容的重要途径。现有药效物质的筛选及评价多为基于特定的靶点进行挖掘,少有双向同时研究药效物质和作用靶标,难以阐释中药多成分-多靶点特性。本项目建立人非小细胞肺癌A549细胞膜/亲和超滤-HPLC-MS方法,并进行了系统的方法学考察及优化。将该方法用于莪术-三棱药对中潜在的抗肺癌药效物质的筛选,通过筛选鉴定发现莪术-三棱药对药效物质有原莪术醇和莪术烯醇,并通过细胞水平的抗肺癌活性评价,初步验证了其抗肺癌活性。此外,本研究还对莪术-三棱药对中可能作用的靶标进行了挖掘,通过药效学、转录组学及生物信息学通路分析的挖掘,Western Blot等方式对相关通路蛋白进行验证,挖掘出莪术-三棱药对发挥抗非小细胞肺癌作用与细胞周期相关信号轴CDK6-Rb-E2F1有关。上述工作的完成,为抗肿瘤中药药效物质的发现及靶标的挖掘提供新思路,也为莪术-三棱药对的临床应用提供理论参考。
基于CDK6-Rb-E2F1信号轴探究莪术-三棱药对挥发油抗肺癌药效物质和作用机制
  • 批准号:
    MS25H280054
  • 项目类别:
    省市级项目
  • 资助金额:
    0.0万元
  • 批准年份:
    2025
  • 负责人:
    林园园
  • 依托单位:
国内基金
海外基金